SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19

被引:13
作者
Liang, Hong-Yu [1 ]
Wu, Yuyan [2 ,3 ]
Yau, Vicky [4 ]
Yin, Huan-Xin [1 ]
Lowe, Scott [5 ]
Bentley, Rachel [5 ]
Ahmed, Mubashir Ayaz [6 ]
Zhao, Wenjing [7 ]
Sun, Chenyu [7 ]
机构
[1] Anhui Med Univ, Sch Clin Med 2, Hefei 230032, Peoples R China
[2] First Peoples Hosp Hefei, 390 N Huaihe Rd, Hefei 230061, Peoples R China
[3] Philippine Womens Univ, Sch Nursing, 1743 Taft Ave, Manila 1004, Philippines
[4] Columbia Univ, Div Oral & Maxillofacial Surg, Irving Med Ctr, 622W 168th St, New York, NY 10032 USA
[5] Kansas City Univ, Coll Osteopath Med, 1750 Independence Ave, Kansas City, MO 64106 USA
[6] AMITA Hlth St Joseph Hosp Chicago, 2900 N Lake Shore Dr, Chicago, IL 60657 USA
[7] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Nantong Western Rd 98, Yangzhou 225000, Jiangsu, Peoples R China
关键词
COVID-19; SARS-CoV-2; variants; vaccines; molecular therapeutic target; RECEPTOR-BINDING DOMAIN; DELTA VARIANT; MUTATIONS; ESCAPE; SPIKE; ACE2; NEUTRALIZATION; INFECTION; ANAKINRA; SCOTLAND;
D O I
10.3390/vaccines10091538
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants.
引用
收藏
页数:27
相关论文
共 50 条
  • [31] COVID-19: implications of SARS-CoV-2 in Colombia
    Almeida-Espinosa, Alexander
    Sarmiento-Ardila, Jorge A.
    GACETA MEDICA DE MEXICO, 2020, 156 (04): : 334 - 338
  • [32] Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
    Zhang, Yandi
    Banga Ndzouboukou, Jo-Lewis
    Gan, Mengze
    Lin, Xiaosong
    Fan, Xionglin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [33] COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants
    Rashed Noor
    Saadia Shareen
    Muntasir Billah
    Bulletin of the National Research Centre, 46 (1)
  • [34] Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants
    Ballesteros-Sanabria, Laura
    Pelaez-Prestel, Hector F.
    Ras-Carmona, Alvaro
    Reche, Pedro A.
    BIOMEDICINES, 2022, 10 (05)
  • [35] Importance of the SARS-CoV-2 genome and spike protein in the immunopathogenesis of COVID-19 and the efficacy of vaccines
    Jimenez-Morales, Silvia
    Perez-Amado, Carlos J.
    Montufar-Robles, Isela
    Fragoso, Jose M.
    Aranda-Uribe, Ivan S.
    Ramos-Puga, David A.
    Martinez-Flores, Angel E.
    Ramirez-Bello, Julian
    CIRUGIA Y CIRUJANOS, 2023, 91 (02): : 268 - 276
  • [36] SARS-CoV-2 (COVID-19): New Discoveries and Current Challenges
    Soufi, Ghazaleh Jamalipour
    Hekmatnia, Ali
    Nasrollahzadeh, Mahmoud
    Shafiei, Nasrin
    Sajjadi, Mohaddeseh
    Iravani, Parisa
    Fallah, Salman
    Iravani, Siavash
    Varma, Rajender S.
    APPLIED SCIENCES-BASEL, 2020, 10 (10):
  • [37] SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
    Tatsi, Elizabeth-Barbara
    Filippatos, Filippos
    Michos, Athanasios
    EPIDEMIOLOGY & INFECTION, 2021, 149 : 536 - 544
  • [38] COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants
    Stefanelli, Paola
    Rezza, Giovanni
    VACCINES, 2022, 10 (06)
  • [39] COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern
    Zeyaullah, Md.
    AlShahrani, Abdullah M.
    Muzammil, Khursheed
    Ahmad, Irfan
    Alam, Shane
    Khan, Wajihul Hasan
    Ahmad, Razi
    FRONTIERS IN GENETICS, 2021, 12
  • [40] The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice
    Miteva, Dimitrina
    Kitanova, Meglena
    Batselova, Hristiana
    Lazova, Snezhina
    Chervenkov, Lyubomir
    Peshevska-Sekulovska, Monika
    Sekulovski, Metodija
    Gulinac, Milena
    Vasilev, Georgi V.
    Tomov, Luchesar
    Velikova, Tsvetelina
    VACCINES, 2023, 11 (07)